Cochidol Tablet

The long-term use of colchicine is established for FMF and the prophylaxis of gout flares, but the safety and efficacy of repeat treatment for gout flares has not been evaluated. The dosing regimens for colchicine tablets are different for each indication and must be individualized. The recommended dosage of colchicine tablets depends on the patient’s age, renal function, hepatic function and use of coadministered drugs.

Directions from the U.S. FDA-approved label for Colchicine — your doctor or pharmacist may advise differently.

Patients with renal or hepatic impairment should not be given colchicine tablets in conjunction with P-gp or strong CYP3A4 inhibitors (this includes all protease inhibitors except fosamprenavir). In these patients, life-threatening and fatal colchicine toxicity has been reported with colchicine taken in therapeutic doses. Patients with renal or hepatic impairment should not be given colchicine tablets in conjunction with P-gp or strong CYP3A4 inhibitors ( Error! Hyperlink reference not valid.

Excerpt from the U.S. FDA-approved label for Colchicine. Talk to a pharmacist or doctor before use.

Fatal overdoses have been reported with colchicine in adults and children. Keep colchicine tablets out of the reach of children ( Error! Hyperlink reference not valid., Error! Hyperlink reference not valid. )., Blood dyscrasias: myelosuppression, leukopenia, granulocytopenia, thrombocytopenia and aplastic anemia have been reported ( Error! Hyperlink reference not valid. )., Monitor for toxicity and if present consider temporary interruption or discontinuation of colchicine ( Error! Hyperlink reference not valid., Error! Hyperlink reference not valid., Error! Hyperlink reference not valid., Error!

Warnings and precautions excerpt from the U.S. FDA-approved label for Colchicine — not a complete list. Talk to a pharmacist or doctor before use.

Prophylaxis of Gout Flares: The most commonly reported adverse reaction in clinical trials of colchicine for the prophylaxis of gout was diarrhea. Treatment of Gout Flares: The most common adverse reactions reported in the clinical trial with colchicine tablets for treatment of gout flares were diarrhea (23%) and pharyngolaryngeal pain (3%).

Excerpt from the U.S. FDA-approved label for Colchicine — not a complete list. Talk to a pharmacist or doctor about side effects.

4 brands · 3 makers in the NepalDoc catalog — see the full Colchicine guide →

Storage Store at 20° to 25°C (68° to 77°F). Protect from light.

Storage information from the U.S. FDA-approved label for Colchicine.